FERNANDO
MORENO ANTÓN
Profesor asociado de Ciencias de la Salud
Publications (38) FERNANDO MORENO ANTÓN publications
2024
-
A retrospective study of do-not-do practice recommendations in metastatic breast cancer in Spain
Revista de Senologia y Patologia Mamaria, Vol. 37, Núm. 3
-
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study
Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172
-
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort
Breast Cancer Research and Treatment, Vol. 206, Núm. 3, pp. 551-559
-
Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2160-2169
2023
-
Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab
JAMA Oncology, Vol. 9, Núm. 6, pp. 841-846
-
Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study
Cancers, Vol. 15, Núm. 18
-
Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2665-2678), 10.1007/s12094-023-03203-8)
Clinical and Translational Oncology
-
Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors
International Journal of Cardiology, Vol. 382, pp. 52-59
-
Expert design thinking workshops to analyze users’ perceived applicability of NUTRI-ONCOCARE algorithm to prevent and treat malnutrition in cancer patients under routine clinical practice conditions in Spain: the ALLIANCE study
Supportive Care in Cancer, Vol. 31, Núm. 9
-
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
Therapeutic Advances in Medical Oncology, Vol. 15
-
Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors
International Journal of Molecular Sciences, Vol. 24, Núm. 14
-
SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2665-2678
2022
-
Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor
Frontiers in Oncology, Vol. 12
-
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
BMC Cancer, Vol. 22, Núm. 1
-
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)
European Journal of Cancer, Vol. 161, pp. 26-37
-
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
Breast, Vol. 66, pp. 77-84
2021
-
Pembrolizumab plus gemcitabine in the subset of triple-negative advanced breast cancer patients in the geicam/2015-04 (Pangea-breast) study
Cancers, Vol. 13, Núm. 21
-
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer
Human Genetics and Genomics Advances, Vol. 2, Núm. 3